JAEA
  • help
  • PC | SP
  • JP | EN
          
Refine your search：     
Report No.
 - 
Clear All
Search Results: Records 1-5 displayed on this page of 5
  • 1

Presentation/Publication Type

Initialising ...

Refine

Journal/Book Title

Initialising ...

Meeting title

Initialising ...

First Author

Initialising ...

Keyword

Initialising ...

Language

Initialising ...

Publication Year

Initialising ...

Held year of conference

Initialising ...

Save select records

Journal Articles

Neutron imaging of generated water inside polymer electrolyte fuel cell using newly-developed gas diffusion layer with gas flow channels during power generation

Nasu, Mitsunori*; Yanai, Hiroshi*; Hirayama, Naoki*; Adachi, Hironori*; Kakizawa, Yu*; Shirase, Yuto*; Nishiyama, Hiromichi*; Kawamoto, Teppei*; Inukai, Junji*; Shinohara, Takenao; et al.

Journal of Power Sources, 530, p.231251_1 - 231251_11, 2022/05

https://doi.org/10.1016/j.jpowsour.2022.231251
 Times Cited Count：16 Percentile：89.77(Chemistry, Physical)

Journal Articles

Design, synthesis, and evaluation of [$$^{188}$$Re]Organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels

Uehara, Tomoya*; Koike, Miho*; Nakata, Hideo*; Hanaoka, Hirofumi*; Iida, Yasuhiko*; Hashimoto, Kazuyuki; Akizawa, Hiromichi*; Endo, Keigo*; Arano, Yasushi*

Bioconjugate Chemistry, 18(1), p.190 - 198, 2007/01

https://doi.org/10.1021/bc0602329
 Times Cited Count：20 Percentile：55.24(Biochemical Research Methods)

Renal localization of radiolabeled antibody fragments constitutes a problem in targeted imaging and radiotherapy. To estimate the applicability of the molecular design to metallic radionuclides, [$$^{188}$$Re]tricarbonyl(cyclopentadienylcarbonate)rhenium ([$$^{188}$$Re]CpTR-COOH) was conjugated with maleoyl-glycyl-lysine to prepare [$$^{188}$$Re]CpTR-GK. The cleavage of the glycyl-lysine linkage of the compound generates a glycine conjugate of [$$^{188}$$Re]CpTR-Gly. [$$^{188}$$Re]CpTR-GK was conjugated to thiolated Fab fragments to prepare [$$^{188}$$Re]CpTR-GK-Fab. The biodistribution of radioactivity after injection of [$$^{188}$$Re]CpTR-GK-Fab was compared with that of [$$^{188}$$Re]CpTR-Fab. [$$^{188}$$Re]CpTR-GK-Fab exhibited significantly lower renal radioactivity levels than did [$$^{188}$$Re]CpTR-Fab. The analysis of urine samples collected for 6 h postinjection of [$$^{188}$$Re]CpTR-GK-Fab showed that [$$^{188}$$Re]CpTR-Gly was the major radiometabolite. In tumor-bearing mice, [$$^{188}$$Re]CpTR-GK-Fab significantly reduced renal radioactivity levels without impairing the radioactivity levels in tumor. These findings indicate that the molecular design of radioparmaceuticals labeled with metallic radionuclides can be useful by using a radiometal chelate of high inertness and by designing a radiometabolite of high urinary excretion when released from antibody fragments following cleavage of a glycyl-lysine linkage. This study also indicates that a change in chemical structure of a radiolabel attached to a glycyl-lysine linkage significantly affected enzymes involved in the hydrolysis reaction.

Journal Articles

Assessment of $$^{186}$$Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones

Uehara, Tomoya*; Jin, Z. L.*; Ogawa, Kazuma*; Akizawa, Hiromichi*; Hashimoto, Kazuyuki; Nakayama, Morio*; Arano, Yasushi*

Nuclear Medicine and Biology, 34(1), p.79 - 87, 2007/01

https://doi.org/10.1016/j.nucmedbio.2006.10.001
 Times Cited Count：23 Percentile：56.61(Radiology, Nuclear Medicine & Medical Imaging)

In this study, a key factor affecting the pharmacokinetics of a chelate-conjugated BP was investigated to estimate the validity and the applicability of molecular design. Chemically inert and well-characterized [$$^{186}$$Re]CpTR-Gly was conjugated with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate and purified by HPLC to prepare [$$^{186}$$Re]CpTR-Gly-APD. Plasma stability, plasma protein binding, hydroxyapatite (HA) binding and the pharmacokinetics of [$$^{186}$$Re]CpTR-Gly-APD were compared with those of $$^{186}$$Re 1-hydroxyethylidene-1,1-diphosphonate (HEDP). The HPLC-purified [$$^{186}$$Re]CpTR-Gly-APD showed higher plasma stability, higher HA binding, higher bone accumulation and lower plasma protein binding than did $$^{186}$$Re -HEDP. Although $$^{186}$$Re -HEDP possessed HA binding and bone accumulation similar to those of [$$^{186}$$Re]CpTR-Gly-APD, the specific activity of $$^{186}$$Re -labeled BPs was found to play a crucial role in bone accumulation and blood clearance. Thus, the molecular design of chelate-conjugated BP would be useful for the development of bone-seeking radiopharmaceuticals with a variety of radionuclides by selecting chelating molecules that provide high specific activities.

Oral presentation

Design of bone-targeted labeled oligoaspartate with $$^{99m}$$Tc and $$^{186/188}$$Re

Kiyota, Sachiko*; Uehara, Tomoya*; Ishii, Daisuke*; Akizawa, Hiromichi*; Hashimoto, Kazuyuki; Arano, Yasushi*

no journal, , 

no abstracts in English

Oral presentation

Development of $$^{76}$$Br-labeled antibody fragments for reduction of non-target radioactivity

Hanaoka, Hirofumi*; Watanabe, Shigeki; Watanabe, Satoshi; Ohshima, Yasuhiro; Uehara, Tomoya*; Akizawa, Hiromichi*; Iida, Yasuhiko*; Ishioka, Noriko; Arano, Yasushi*; Endo, Keigo*

no journal, , 

no abstracts in English

5 (Records 1-5 displayed on this page)
  • 1